Coastlands Capital details ADIAL Pharmaceuticals (ADIL) stock and warrant stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Coastlands Capital LP, a more than ten percent owner of ADIAL PHARMACEUTICALS, INC., has filed an initial Form 3 reporting its indirect holdings. The filing shows indirect ownership of 348,322 shares of common stock and Pre-Funded Warrants exercisable into 3,637,818 shares of common stock.
The Pre-Funded Warrants are exercisable at an exercise price of $0.001 per share and have no expiration date, according to the disclosure. A holder may not exercise these warrants if, after exercise, it would beneficially own more than 4.99% of the issuer’s outstanding common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Coastlands Capital LP
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Pre-funded Warrant | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Pre-funded Warrant — 3,637,818 shares (Indirect, By Coastlands Capital LP);
Common Stock — 348,322 shares (Indirect, By Coastlands Capital LP)
Footnotes (1)
- Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
Key Figures
Indirect common shares: 348,322 shares
Pre-funded warrant underlying shares: 3,637,818 shares
Warrant exercise price: $0.001 per share
+2 more
5 metrics
Indirect common shares
348,322 shares
Indirectly held common stock reported by Coastlands Capital LP
Pre-funded warrant underlying shares
3,637,818 shares
Common shares underlying pre-funded warrants held indirectly
Warrant exercise price
$0.001 per share
Exercise price of pre-funded warrants to purchase ADIL common stock
Beneficial ownership cap
4.99%
Maximum post-exercise beneficial ownership allowed for warrant holder
Ownership status
More than ten percent owner
Reporting person status indicated in Form 3 metadata
Key Terms
Pre-Funded Warrants, beneficial ownership, pecuniary interest, ten percent owner, +1 more
5 terms
Pre-Funded Warrants financial
"The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership financial
"Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein"
ten percent owner regulatory
"is_ten_percent_owner": 1"
beneficially own more than 4.99% regulatory
"may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares"
FAQ
What did Coastlands Capital LP report in its Form 3 for ADIL?
Coastlands Capital LP reported indirect holdings in ADIAL Pharmaceuticals common stock and pre-funded warrants. The filing lists 348,322 common shares and pre-funded warrants exercisable into 3,637,818 common shares at a $0.001 exercise price, establishing its status as a more than ten percent owner.
What are the key terms of Coastlands Capital LP’s pre-funded warrants in ADIL?
Coastlands Capital LP holds pre-funded warrants to purchase 3,637,818 ADIAL common shares at a $0.001 exercise price. The warrants have no expiration date and are exercisable at any time, subject to a 4.99% beneficial ownership cap on post-exercise common stock ownership.
What is the 4.99% beneficial ownership limitation mentioned in the ADIL Form 3?
The filing states a holder of the pre-funded warrants cannot exercise them if, together with affiliates, it would beneficially own more than 4.99% of ADIAL's outstanding common stock after exercise. This cap limits how much of the company can be held via warrant exercises.
Are there any recent buy or sell transactions by Coastlands Capital LP in ADIL in this filing?
The Form 3 functions as an initial ownership report, not a trade summary. It lists Coastlands Capital LP’s indirect common stock and pre-funded warrant positions but does not show any explicit purchase or sale transactions associated with these ADIAL Pharmaceuticals holdings.